Emcure Pharmaceuticals Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹960 - ₹1008
- Lot size
- 14 shares
- Issue amount
- ₹1,952.03 cr
- Total subscription
- 68.4×
- Opens
- 3 Jul 2024
- Closes
- 5 Jul 2024
- Allotment
- 8 Jul 2024
- Listing
- 10 Jul 2024
Offer at a glance
Issue overview
- Issue size
- 1,93,65,347 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹13,440
- Fresh issue
- ₹800.58 cr
- Offer for sale
- ₹1,151.45 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,112
- Issue type
- Bookbuilding IPO
- Shares before issue
- 18,08,52,116
- Shares after issue
- 18,87,88,623
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 14 | ₹14,112 |
| sHNI | 15 | 210 | ₹2,11,680 |
| bHNI | 994 | 994 | ₹10,01,952 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| HNIs (10L+) | 9,174 | 1,00,845 |
| HNIs (2-10L) | 4,587 | 1,67,799 |
| RETAIL | 4,81,654 | 26,01,844 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 388.41 | 74,278.71 |
| RETAIL | 679.71 | 5,000.2 |
| NIB | 291.3 | 14,366.19 |
| HNIs 2+ | 97.1 | 3,704.52 |
| HNIs 10+ | 194.2 | 10,661.67 |
| EMPLOYEES | 10.98 | 96.73 |
Financial performance
Company financials
in Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|
| EPS | 27.54 | 29.42 | 36.62 |
| ROE | 16.9 | 21.2 | 33.23 |
| ROCE | 19.37 | 22.01 | 29.69 |
| RONW | 16.87 | 21.27 | 33.32 |
| PRE IPO(PE) | 34.55 | 0 | 0 |
| POST IPO(PE) | 36.07 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Emcure Pharmaceuticals Limited, incorporated in 1981, is a leading Indian pharmaceutical company engaged in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products across multiple therapeutic areas. Ranked 13th in domestic sales and 4th in market share in covered markets for MAT September 2023, Emcure is a leader in the gynaecology and HIV antiviral segments. With domestic sales contributing over 50% of total revenue and growing at a CAGR of 10.80% between September 2019 and September 2023, the company has outpaced the Indian pharmaceutical market. It operates five research facilities in India, employing 552 scientists and filing over 1,800 global regulatory documents, including 201 granted patents. Emcure's 13 manufacturing facilities in India produce a wide range of pharmaceutical and biopharmaceutical products, including chiral molecules, iron molecules, and cytotoxic substances. Supported by over 5,000 field personnel and 5,000 stockists across 37 carry-and-forward agents, the company maintains an extensive marketing and distribution network, ensuring strong engagement with healthcare providers and efficient product availability.
Strengths
- Strong Domestic Market Presence: The company is strategically positioned to capitalize on its established foothold in the domestic market.
- Proven Brand Development Expertise: A track record of successfully building and strengthening brand identity, enhancing market recognition.
- Expanding Global Portfolio: A rapidly growing and diverse product range catering to international markets, driving global business growth.
Risk factors
- Manufacturing and Quality Risks: Any lapses in manufacturing processes or quality control could harm the company's reputation, invite regulatory scrutiny, and lead to potential legal liabilities.
- Quality Standard Compliance: Non-compliance with industry quality standards may result in product liability claims, affecting financial stability and operational efficiency.
- Supply Chain Vulnerabilities: Dependence on outsourced raw materials and finished goods exposes the company to risks of supply chain disruptions and cost fluctuations, potentially impacting pricing, profitability, and overall business performance.
Promoters
Satish Mehta
Sunil Mehta
Registrar & documents
Lead manager
Kotak Mahindra Capital Company, Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Plot No. P-1 and P-2,, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune -411 057
+91 20 3507 0033
[email protected]Company website ↗Understanding EMCURE IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.